Hospital Universitario De Navarra — Clinical Trial Site

228 Registered trials

100 Currently recruiting

Organisation

Hospital Universitario De Navarra

Location

Pamplona, Spain

Identifier

ORG-100044636

Address

Irunlarrea Kalea 3, 31008, Spain

Departments

#2040: ensayos clínicos
#2205:Pediatric Endocrinology
#2607: Reumatología
#3408 - Reumatología
#3470: Medicina Interna
#7010: Hematología
#9110 Hemat/Transfusion Med
2804: Medicina Interna
2915: Hematology
3408: Reumatología
3655: Pediatría
5510: Neumologia
6902: Oncología
7007: Oncologia
ALERGOLOGÍA
Allergology
Cardiología
Cardiology
cirugia
Cirugía General y Aparato Digestivo
Departamento de Oncología
Department of Endocrinology
Digestive
Digestive system
Digestivo
Endocrinología y Nutrición
Endocrinology
ES10003: Gastroenterology
ES10006: Gastroenterology
ES10018: Hematología
Gastroenterologia
GASTROENTEROLOGY
Gastroenterology (inflammatory bowel disease section)
Ginecología
Haematology
Haematology and Hemotherapy
Hematología
hematology
Hematology Service
Hepatology
Hospital Universitario de Navarra (#1)
Internal Medicine
Medical Oncology
Medical Oncology Department
Medicina Interna
N/A
Nephrology
Nephrology department
Neumología
Neumology
Neurología
Neurologia Pediatrica
Neurology
Neurology Department
Neuropediatria
Oncologia
Oncología médica
Oncologia Radioterapica
Oncology
Oncology department
Oncology service
Opthalmology service
Pediatria
Pediatric
Pediatric oncology
Pediatrics
Pneumology
Pulmonology Service
Radiation Oncology
Respiratory
Respiratory medicine
Rheumatology
Servicio de digestivo
Servicio de Cardiologia
Servicio de Hematología
Servicio de Neumología
Servicio de Oncologia Medica
Servicio de Oncología y Hematología Pediátricas
Servicio Neumologia
servicio oncologia
Urology

Clinical trials at this site (228)

Search interface

CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL) Ended

2023-504262-32-01 Cerebral Embolectomy in patients with acute stroke 5 2023-11-16
A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants… Ended

2023-504338-24-00 ESKD participants with history of secondary hyperparath 5 2023-11-09
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended

2022-502227-22-00 Autoimmune disease 4 2023-10-25
Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended

2022-501523-24-00 Cutaneous Lupus Erythematosus (CLE) 4 2023-10-12
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended

2023-504239-41-00 Hepatitis B, Chronic 5 2023-01-09
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI… Ended

2023-504270-38-00 In participants with PD-L1–positive and systemic therap 4 2022-10-18
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic M… Ended

2023-507208-30-00 Diabetic Macular Edema (DME) 10 2022-09-20
RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended

2023-505441-69-00 refractory, advanced gastro-oesophageal cancer 5 2022-05-17
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T… Ended

2023-505097-16-00 Ovarian Neoplasms 4 2022-04-04
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300) Ended

2024-511187-81-00 Colorectal Cancer (CRC) 5 2022-03-28
A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma … Ended

2023-509917-35-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2022-03-21
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER) Ended

2024-516824-32-00 Covid19 Corona Virus Infection 5 2021-11-15
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic… Ended

2024-517251-12-00 Recurrent or metastatic head and neck squamous cell car 5 2021-11-02
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended

2024-510744-31-00 Giant cell arteritis (GCA) 5 2021-10-06
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended

2023-508340-22-00 metastatic or unresectable, recurrent HNSCC 4 2021-08-11
A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma… Ended

2023-508342-17-00 metastatic or unresectable, recurrent HNSCC 4 2021-08-11
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
Lighthouse II study Ended

2024-517054-94-00 AMYOTROPHIC LATERAL SCLEROSIS 5 2021-07-05
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
A Study to Evaluate Effects of RO7121661 and RO7247669 Compared With Nivolumab in Advanced or Metastatic Squamous Cell Carcinoma of the Esop… Ended

2024-511403-41-00 Advanced or metastatic squamous cell carcinoma of the e 4 2021-04-14
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaps… Ended

2024-515582-33-00 Relapsed/Refractory Multiple Myeloma (RRMM) 1 2020-10-26